文献速递物质与行为成瘾心境障碍会诊联络精神医学

GLP-1疗法用于成瘾与精神健康共病的前景:何去何从?综述

Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

本综述讨论GLP-1疗法在酒精及其他物质使用障碍(ASUDs)与精神健康共病中的现状、缺口与机会。临床前证据一致显示GLP-1受体激动剂减少药物摄取与成瘾行为,观察性队列提示ASUD相关结局改善,随机对照试验有限且结果不一但总体有希望信号,GLP-1RAs似不增加精神病理风险。结论认为需RCT确定安全性与有效性,GLP-1疗法有重定位潜力但诸多问题待研究。

要点

  • 临床前证据一致显示GLP-1受体激动剂减少药物摄取与成瘾行为,研究以酒精为主也涉及尼古丁、阿片与精神兴奋剂。
  • 观察性队列提示因其他适应证使用GLP-1RAs者ASUD相关结局改善,RCT有限且结果混合但总体有希望信号。
  • GLP-1RAs似不导致或增加精神病理风险,部分近期研究提示对精神健康结局有益但需更多工作。

核心结论

  • 临床前与观察性临床证据支持研究GLP-1疗法用于ASUDs的合理性,RCT正在出现且在此关键节点亟需确定安全性与有效性。
  • 在RCT结果待出前,GLP-1疗法有潜力重定位用于ASUDs,但剂量、疗程、快速耐受、停药影响、个体差异与反应预测因素、作用机制、与精神健康和躯体共病的交叉、成本与公平可及性等问题需进一步研究。

研究设计与样本

  • 本文为综述,讨论GLP-1疗法在ASUDs、精神健康考量及该领域缺口与机会中的当前图景。

主要发现

  • 多个实验模型与物种的临床前证据一致显示GLP-1受体激动剂(GLP-1RAs)减少药物摄取及其他成瘾行为。
  • 研究至今主要聚焦酒精,但尼古丁、阿片与精神兴奋剂也有研究。
  • 使用电子健康记录的观察性队列研究提示,因其他适应证接受GLP-1RAs治疗者ASUD相关结局改善。
  • 随机对照试验(RCT)有限,结果混合但总体有希望信号,多项RCT正在进行或即将开始。
  • 尽管早期有药物警戒警报,GLP-1RAs似不导致或增加精神病理(如抑郁、自杀意念和/或行为)风险,部分近期研究提示对精神健康结局有益但需更多工作。

临床怎么用

  • 临床应了解GLP-1疗法在ASUDs中的证据主要来自临床前与观察性研究,RCT证据有限且结果混合。
  • 对因其他适应证使用GLP-1RAs者,现有证据未提示增加精神病理风险,部分研究提示精神健康结局可能获益。
  • 在RCT结果待出前,将GLP-1疗法重定位用于ASUDs需谨慎,并关注剂量、疗程、停药影响、个体差异、机制、共病交叉、成本与公平可及性等未决问题。

局限性

  • RCT有限且结果混合,尚不能确定GLP-1疗法在ASUDs人群中的安全性与有效性。
  • 研究至今主要聚焦酒精,尼古丁、阿片与精神兴奋剂的研究相对有限。
  • 剂量、疗程、快速耐受、停药影响、个体差异与反应预测因素、作用机制、与精神健康和躯体共病的交叉、成本与公平可及性等问题需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Glucagon-like peptide-1 (GLP-1) therapies have revolutionized the management of chronic conditions like obesity and diabetes. Consistent with the overlap between feeding and metabolic pathways and those mediating addictive behaviors, growing evidence suggests that GLP-1 therapies may also be beneficial for treating alcohol and other substance use disorders (ASUDs). This review discusses the current landscape of GLP-1 therapies in the context of ASUDs, mental health considerations, and gaps and opportunities in this field. OBSERVATIONS: Preclinical evidence across several experimental models and species consistently shows that GLP-1 receptor agonists (GLP-1RAs) reduce drug intake and other addictive behaviors. Research to date has primarily focused on alcohol; however, nicotine, opioids, and psychostimulants have also been studied. Observational cohort studies using electronic health records suggest improvements in ASUD-related outcomes among people treated with GLP-1RAs for other indications. Randomized clinical trials (RCTs) have been limited, yielding mixed results but overall promising signals. Several RCTs are ongoing or about to start. Despite some early pharmacovigilance alarms, GLP-1RAs do not seem to cause or increase the risk of psychopathology (eg, depression, suicidal ideation and/or behavior). Some recent studies suggest beneficial effects of GLP-1RAs on mental health outcomes, but more work is needed. CONCLUSIONS AND RELEVANCE: The rationale for studying GLP-1 therapies for ASUDs is supported by preclinical and observational clinical evidence. RCTs are emerging and critically needed at this juncture to determine the safety and efficacy of GLP-1 therapies in people with ASUDs. Pending results from RCTs, GLP-1 therapies have the potential to be repurposed for ASUDs. However, there are several relevant questions in need of further investigation, including the specifics of treatment with GLP-1 therapies in the context of addiction (eg, dose, duration, tachyphylaxis, impact of discontinuation), individual differences and potential predictors of response, mechanisms of action, intersection with mental health and medical comorbidities, cost, and fair access to these treatments.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Farokhnia M, Leggio L. Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review. JAMA Psychiatry. 2026. PMID: 41563749. doi:10.1001/jamapsychiatry.2025.4308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。